Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) Cash & Equivalents: 2021

Historic Cash & Equivalents for Cardiol Therapeutics (CRDL) over the last 1 years, with Dec 2021 value amounting to $66.9 million.

  • Cardiol Therapeutics' Cash & Equivalents fell 197.27% to -$11.3 million in Q3 2022 from the same period last year, while for Sep 2022 it was -$11.3 million, marking a year-over-year decrease of 197.27%. This contributed to the annual value of $66.9 million for FY2021, which is N/A change from last year.
  • Cardiol Therapeutics' Cash & Equivalents amounted to $66.9 million in FY2021.
  • In the past 5 years, Cardiol Therapeutics' Cash & Equivalents registered a high of $66.9 million during FY2021, and its lowest value of $66.9 million during FY2021.
  • Moreover, its 1-year median value for Cash & Equivalents was $66.9 million (2021), whereas its average is $66.9 million.